<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Ib Postgrad Med</journal-id><journal-id journal-id-type="iso-abbrev">Ann Ib Postgrad Med</journal-id><journal-id journal-id-type="publisher-id">AIPM</journal-id><journal-title-group><journal-title>Annals of Ibadan Postgraduate Medicine</journal-title></journal-title-group><issn pub-type="ppub">1597-1627</issn><publisher><publisher-name>Association of Resident Doctors (ARD), University College Hospital, Ibadan</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27162517</article-id><article-id pub-id-type="pmc">4853878</article-id><article-id pub-id-type="publisher-id">AIPM-13-72</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>COMPARATIVE EFFICACY AND SAFETY OF CEFIXIME AND CIPROFLOXACIN IN THE MANAGEMENT OF ADULTS WITH COMMUNITY-ACQUIRED PNEUMONIA IN IBADAN, NIGERIA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ige</surname><given-names>O.M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Okesola</surname><given-names>A.O.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine, University College Hospital, Ibadan, Nigeria.</aff><aff id="aff2"><label>2</label>Dept. of Medical Micro. &#x00026; Parasitology, College of Medicine, University of Ibadan, Ibadan, Nigeria.</aff><author-notes><corresp><italic>Correspondence:</italic><bold>Dr. O.M. Ige</bold> Pulmonary Unit, Department of Medicine, University College Hospital, Ibadan, Nigeria. E-mail: <email>olusojiige@yahoo.com</email> Mobile phone: +2348030658080</corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>13</volume><issue>2</issue><fpage>72</fpage><lpage>78</lpage><permissions><copyright-statement>&#x000a9; Association of Resident Doctors, UCH, Ibadan</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0</uri>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Initial antibiotic therapy in upper and lower respiratory tract
infections is usually empirical. However, the decreasing susceptibility of
respiratory pathogens to antibacterials have raised concerns about the decreasing
efficacy of currently available antibiotics.</p></sec><sec><title>Objective:</title><p>This study was conducted to compare the efficacy and safety of cefixime
and ciprofloxacin in the empirical treatment of community-acquired pneumonia
among adult Nigerian patients in Ibadan.</p></sec><sec><title>Method:</title><p>This was an open-labelled, randomized, parallel-group study of seventy-three
(73) radiologically and bacteriologically confirmed adult cases of
community-acquired pneumonia, between July 1 and September 31, 2011 at two
health care facilities in Ibadan, Nigeria. All of these patients had severity index
(CURB 65) scores of either 1 or 2. They were treated with either Cefixime, 400mg
twice daily or Ciprofloxacin 500mg twice daily for 14 days. They were evaluated
four times during the course of their treatment for clinical responses, radiological
and bacteriological clearances and safety of therapy.</p></sec><sec><title>Results:</title><p>There were 39 (53.4%) patients in the Cefixime group and 34(46.6%) in
Ciprofloxacin group. On day 7, patients on cefixime had a statistically significant
lower temperature than patients on ciprofloxacin (P&#x0003c;0.01). By day 14, only 10.3%
of patients in cefixime group still had persistent residual radiological changes
compared to 38.2% in the ciprofloxacin group (P &#x0003c; 0.01). Bacteria cure was obtained
in 96% of the patients in the cefixime group and 83% in the ciprofloxacin group.</p></sec><sec><title>Conclusion:</title><p>Cefixime was found to be superior to ciprofloxacin in terms of efficacy
in the treatment of community-acquired pneumonia in adults in Nigeria. However,
both antibiotics were well-tolerated by all the patients as there were no reports or
documentation of adverse events.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Cefixime</kwd><kwd>Efficacy</kwd><kwd>Safety</kwd><kwd>Community-acquired pneumonia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Respiratory tract infections (RTIs) are amongst the most widespread and serious infections accounting for over 50 million deaths globally each year.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> They are also the most common reason for physician's visit and antibiotic prescription.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> The prevalence of pneumonia among adults with respiratory symptoms suggesting pneumonitis ranges from only 3% in a general outpatient setting to 28% in emergency department. <sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> Community-acquired pneumonia (CAP) is a common cause of hospital admission in Nigeria, and, in TB patients attending a TB clinic in South-Western Nigeria, 6.4% was found to have <italic>Streptococcal pneumoniae</italic>.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p><p>Initial antibiotic therapy in upper and lower respiratory tract infections is usually empirical, focused towards the most common aetiologic agents, which include, <italic>Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae and Moraxella catarrhalis</italic>.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> However,the decreasing susceptibility patterns of these pathogens, particularly <italic>S.pneumoniae</italic> and <italic>H.influenzae</italic>, to antibacterials have raised concerns about the decreasing efficacy of currently available antibiotics.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> In the United States, almost 100% of clinical <italic>M</italic>. <italic>catarrhalis</italic> and up to 50% of <italic>H</italic>.<italic>influenzae</italic> isolates produce beta-lactamase. Penicillin-resistant strains have been identified worldwide,<sup><xref rid="R9" ref-type="bibr">9</xref></sup> and, resistance to other antibacterials such as cephalosporins, fluoroquinolones and macrolides is increasing among isolates of <italic>S.pneumoniae.</italic><sup><xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R12" ref-type="bibr">12</xref></sup></p><p>Cefixime belongs to the third-generation cephalosporin antibiotics that exert their bactericidal effect by attaching to penicillin-binding proteins and inhibiting peptidoglycan synthesis, thus causing damage to the bacterial cell wall. The third-generation cephalosporins are used all over the world because of their broad spectrum activity against all Gram-negative and positive pathogens and atypical organisms, e.g. Mycoplasma and Chlamydia.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p><p>Ciprofloxacin, also a broad-spectrum, early-generation fluoroquinolone, is one of the cheap and most commonly used antibiotics for most infections including RTI in this community, and, it exhibits bactericidal activity primarily by inhibiting bacterial DNA gyrase. These drugs were acceptable standard antibiotics for the treatment of community-acquired pneumonia during the study period. Even though there are many antibiotics that require less frequent administration, some studies indicate that older antibiotics that have fallen out of favour, are still effective for treatment of community-acquired pneumonia.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> This study was therefore conducted to evaluate the comparative efficacy and safety of Cefixime and Ciprofloxacin in the empirical treatment of CAP among adult Nigerian patients in Ibadan, Nigeria.</p></sec><sec sec-type="materials|methods"><title>PATIENTS AND METHODS</title><sec><title>Study population, enrolment and therapy</title><p>This was an open-labelled, randomized, parallel-group study conducted at the General Out Patient Department of the University College Hospital (UCH), Ibadan and Saint Mary's Catholic Hospital, Eleta, Ibadan, Nigeria, between July 1 and September 31, 2011.</p><p>The first 75 subjects who satisfied the inclusion criteria were randomised into Cefixime and Ciprofloxacin groups. However, 2 of these were lost to follow-up as they failed to turn up for subsequent visits to the clinic, leaving 73 to conclude the study.</p><p>The major inclusion criteria included: adult above 18 years of age, recent onset of fever (&#x0003e;38.3<sup>o</sup>C), cough with purulent expectoration, bacteriologically positive sputum, presence of an infiltrate on chest radiography performed within 72 hours after the first clinical examination, pleuritic chest pain, crackles, new onset of dyspnea, or worsening dyspnea, female of child bearing potential with a negative urine pregnancy test prior to enrolment (including those who were practising birth control, those with tube ligation and those less than 1 year post-menopausal),willingness to partake in the study and provision of a signed informed or witnessed verbal informed consent.</p><p>The key exclusion criteria included: patients with bacteriologically negative sputum, negative chest radiograph, on antibiotics for any infective conditions within the preceding 30 days, hypersensitivity to quinolones or cephalosporins or a severe allergic reaction to any other drug in the past, especially penicillin, patients with other chronic pulmonary diseases like active tuberculosis, bronchiectasis, or active pulmonary malignancies, patients with a life threatening or serious underlying disease, which is unstable, e.g. myocardial infarction, patients with known or suspected renal impairment and/or known creatinine clearance &#x0003c;40ml/min, patients with ALT, AST, or alkaline phosphatase levels 3 times greater than the upper limit of normal, patients who were immuno-compromised including HIV positive patients, patients whose initial clinical status justified immediate hospitalization, and these were provided with hospital admission and excluded from the study.</p><p>A complete medical history was obtained and physical examination conducted on all the patients prior to entry into the study. Patients whose severity index (CURB 65) score were 1 or 2 were enrolled and those whose scores were higher than these were excluded from the study as many of these needed to be admitted. Enrolment was made after obtaining bacteriologically positive sputum and positive chest radiograph results from any of the patients apart from other inclusion criteria. Each eligible patient was assigned by a computer-generated sequence of random numbers to receive either Cefixime, 400mg twice daily or Ciprofloxacin, 500mg twice daily for 14 days.</p><p>Enrolled patients were followed up during treatment at the Medical Out-Patient Department of the respective study hospitals. Each study participant received the first dose of any of the 2 antibiotics on the first day of the study which corresponded to the time after positive radiological and bacteriological reports were obtained.</p><p>This was supervised by the study nurse and patients were then encouraged to take subsequent doses of the respective antimicrobial agent daily till the next follow up clinic visit. Compliance with drug regimen was crosschecked by direct questioning and pill count at every follow up clinic visit. Study participants were followed up on days 1, 3, 7, and 14.</p><p>Prior to enrolment, sputum samples were collected in sterile sputum cups and were transferred to the laboratory in a cold box the same day for laboratory evaluation. Pathogens were isolated and identified from sputa using standard bacteriological methods. Identified pathogens were then subjected to antibiotics susceptibility test to cefixime and ciprofloxacin using the Kirby-Bauer disc diffusion method.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Sputum collection was repeated on days 3, 7 and 14 to check for bacteriological clearance.</p><p>Ten milliliters of blood was obtained by venepuncture for full blood count and blood chemistry evaluation which included aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), total bilirubin, electrolyte &#x00026; urea and serum creatinine.</p><p>The laboratory investigations were conducted at the diagnostic medical microbiology, hematology and chemical pathology laboratories of University College Hospital Ibadan. Full blood count and differentials as well as biochemical parameters were again re-evaluated on day 14. Chest X-rays (posterior anterior &#x00026; lateral views) were taken at the UCH or Saint Mary's Catholic Hospital, Eleta X-ray Departments prior to commencement of treatment and on day 14.</p></sec><sec><title>Efficacy and safety parameters</title><p>Patients were evaluated four times during the course of treatment. The primary efficacy was to evaluate the comparative clinical response at the two arms of treatment on days 3, 7 and 14. Secondary efficacy parameters included the comparative radiological response at the end of therapy and bacterial eradication rate on days 3,7 and 14. The bacterial sensitivity to Cefixime and Ciprofloxacin was determined for each isolated bacteria, irrespective of the treatment group assigned. The organisms were considered sensitive to Cefixime when the inhibition halo was equal to or greater than 19 mm and sensitive to Ciprofloxacin when the halo was equal or greater than 21 mm.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p><p>The bacteriologic response was considered satisfactory if the causative organism had been eradicated with treatment. Radiologic response was considered satisfactory when the lobar consolidation noticed at the beginning of treatment has cleared completely on day 14 of antibiotics therapy as reported by the consultant radiologist.</p><p>The safety end point was to evaluate the incidence of adverse effects and laboratory parameters.</p></sec><sec><title>Statistical analysis</title><p>Data generated was entered using epidata program and the SPSS version 16 was used for further statistical analysis. Frequency tables, graphs and summary index were used for data presentation. The student t-test was used to investigate the statistical significance of the quantitative effects of the two drugs between the two groups.</p></sec><sec><title>Ethical considerations</title><p>All patients enrolled gave written informed consent and the trial was approved by the Joint Ethical Committee of the University College Hospital/ University of Ibadan, Nigeria.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Seventy-five patients that satisfied the inclusion criteria were recruited for this open-labelled, randomised,drug trial but two were lost to follow-up as they failed to turn up for subsequent visits to the clinics as scheduled. One was from each arm of the treatment leaving 39 in the cefixime group and 34 in the ciprofloxacin group. Table <xref ref-type="table" rid="T1">1</xref> shows the anthropometric characteristics of the patients from the two arms of treatment.</p><p>Primary efficacy parameter is the clinical response on follow up in each treatment group. Table <xref ref-type="table" rid="T2">2</xref> shows the clinical features of patients allocated to the 2 treatment groups while Table <xref ref-type="table" rid="T3">3</xref> shows the summary of statistics of patients' clinical characteristics on each day of follow-up in each treatment group.</p><p>The temperature pattern shows that the temperatures decreased slightly in both groups by day 3 but not statistically significant (P&#x0003e;0.2). However, on day 7, patients on cefixime had a statistically significant lower temperature than patients on ciprofloxacin (P&#x0003c;0.01). The same was observed with regards to the respiratory rate. This pattern was maintained on day 14 during the final clinical examination of the patients.</p><p>Table <xref ref-type="table" rid="T4">4</xref> shows the results of the secondary efficacy parameters of the two drugs in terms of their bacterial eradication rates and radiological clearance at follow-up of the patients. The distribution of lung lesions and percentage clearance on days 1 and 14 in the 2 treatment groups is demonstrated in Table <xref ref-type="table" rid="T5">5</xref>. The predominant bacterial aetiology of community-acquired pneumonia in this study was <italic>Staphylococcus aureus 29 (39.7%)</italic>, followed by <italic>Streptococcus pneumoniae 11(15.1%)</italic>, <italic>Klebsiella pneumoniae</italic>10(13.7%), <italic>Escherichia coli</italic> 17(23.3%) and <italic>Proteus mirabilis 6</italic> (8.2%).</p><p>As regards the safety parameters considered for the two drugs, there were no adverse drug effects observed or reported by any of the patients in the two arms of treatment. The liver function tests, urea and creatinine, complete blood counts were essentially of normal values in all the patients at baseline and end of treatment.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Community-acquired pneumonia (CAP) is a cause of substantial morbidity, mortality, and resource utilization worldwide. Despite substantial progress in therapeutic options, CAP remains a significant cause of morbidity and death, and, there continues to be a major controversy concerning the antimicrobial management of this infection.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> The mixed aetiology and the changing susceptibility of pathogens causing CAP, in particular, that of <italic>Streptococcus pneumoniae,</italic> has created a challenge, in some circumstances, to clinicians in terms of optimal outcome.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p><p>Initial antimicrobial therapy is normally given empirically before the bacterial cause of the infection can be determined in the laboratory, and, in many cases, treatment is empirical throughout due to lack of reliable microbiological data. An understanding of the possible pathogens and resistant patterns is therefore helpful in guiding antibiotic choice. A detailed knowledge of the local susceptibility of the potential pathogens would ensure a more appropriate selection of the antimicrobial agent to be used.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> In this environment, ciprofloxacin is the most commonly used antibiotics for management of infections including RTIs, being the most readily available and very cheap, which leads to the comparison of it's efficacy and safety with cefixime in this study.</p><p>The choice of these empirical antibiotics for CAP in this study was in conformity with the guildelines of IDSA (Infectious Disease Society of America)/ATS (American thoracic society)/Canadian guidelines (CIDS,CTS).<sup><xref rid="R20" ref-type="bibr">20</xref>-<xref rid="R23" ref-type="bibr">23</xref></sup> The major criterion that guided the management decision of the CAP patients revolved around the initial assessment of the severity since the oral route can only be recommended in these non-severe (mild to moderate) pneumonia which was the case in this study.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup></p><p>The finding of persistent residual radiological changes in this study is in keeping with the observation of earlier researchers that radiographic response to treatment usually lags behind clinical improvement and pneumococcal pneumonia may take 6 weeks to clear on the chest film.<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> This delay of the radiographic clearing that contrasts with the rapid clinical response seen on the third day of antibiotic treatment was one of the striking findings in this study.</p><p>The results of our study show that cefixime administered at the dose of 400mg twice daily is an effective oral antibiotic treatment in the management of community-acquired pneumonia in adults. This is in keeping with most previous clinical studies that found it very effective for lower respiratory tract infections.<sup><xref rid="R26" ref-type="bibr">26</xref>-<xref rid="R32" ref-type="bibr">32</xref></sup> The efficacy of cefixime in acute exacerbation of chronic bronchitis (AECB) has also been well documented in both comparative and non-comparative clinical studies.<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup>.</p><p>In this study, the predominant cause of community-acquired pneumonia was<italic>Staphylococcus aureus 29 (39.7%)</italic>, followed by <italic>Streptococcus pneumoniae 11(15.1%)</italic>, <italic>Klebsiella</italic>
<italic>pneumoniae</italic>10(13.7%), <italic>Escherichia coli</italic>17(23.3%) and <italic>Proteus mirabilis 6</italic> (8.2%).</p><p>This is contrary to a study conducted in the United States in 2006, where, in approximately 4.2 million ambulatory care visits for CAP, <italic>Streptococcus pneumoniae</italic> was the most commonly identified pathogen.<sup><xref rid="R35" ref-type="bibr">35</xref>-<xref rid="R37" ref-type="bibr">37</xref></sup></p><p>None of the patients experienced vital signs of potential clinical concern or reported any adverse events during the course of study in the two arms of treatment. Cefixime was found to be safe and well tolerated in all the patients which contrasts the previous documentation of mild or moderate diarrhea and epigastric discomfort.<sup><xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref></sup> Thus, cefixime was shown to be superior to ciprofloxacin in the treatment of bacterial pneumonia among adults who have been properly assessed not to need hospitalization in Nigeria.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>The trial was supported by Swipha Pharmaceutical Limited which provided clinical trial materials and other logistic support and for this, we are grateful.</p></ack><sec><title>Limitation of the study</title><p>The clinical efficacy of Cefixime should also be compared with the new-generation fluoroquinolones (clionfloxacin, gemifloxacin, levofloxacin or moxifloxacin) and with another potent third-generation cephalosporins (cefpodoximeproxetil).</p><p>The on-going research will address this and help the clinicians with the right choice of empiric antibiotic treatment of CAP in Nigeria.</p></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="book" publisher-type="book"><person-group person-group-type="author"><name><surname>Thomas Neumark</surname><given-names>Lars Brudin</given-names></name><name><surname>Sven</surname><given-names>Engsro</given-names></name><name><surname>Sigvard</surname><given-names>MO</given-names></name></person-group><collab>World Health Organization</collab><article-title>Burden of Disease Project</article-title><year>2005</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Neumark</surname></name><etal/></person-group><article-title>Trends in number of
consultations and antibiotic prescriptions for
respiratory tract infections between 1999 and 2005
in primary healthcare in Kalmar County, Southern
Sweden</article-title><source>Scand J Pri Health Care</source><year>2009</year><volume>27</volume><fpage>18</fpage><lpage>24</lpage></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Heckerling</surname><given-names>PS</given-names></name><name><surname>Tape</surname><given-names>TG</given-names></name><name><surname>Wigton</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Clinical prediction rule for pulmonary infiltrates</article-title><source>Ann Intern Med</source><year>1990</year><volume>113</volume><fpage>664</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">2221647</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Diehr</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>RW</given-names></name><name><surname>Bushyhead</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prediction
of pneumonia in outpatients with acute cough: a
statistical approach</article-title><source>J Chr Dis</source><year>1984</year><volume>37</volume><fpage>215</fpage><lpage>225</lpage></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="other" publisher-type="journal"><person-group person-group-type="author"><name><surname>Agwu</surname><given-names>E</given-names></name><name><surname>Ohihion</surname><given-names>AA</given-names></name><name><surname>Agba</surname><given-names>MI</given-names></name></person-group><article-title>Incidence of
Streptococcus pneumoniae among patients attending
tuberculosis clinics in Ekpoma, Nigeria</article-title><source>Shiraz EMedicine</source><year>2006</year><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Mandell</surname><given-names>LA</given-names></name><name><surname>Wunderrink</surname><given-names>RG</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Infectious Diseases Society of America/American
Thoracic Society consensus guidelines on the
management of community-acquired pneumonia
in adults</article-title><source>Clin Infect Dis</source><year> 2007</year><volume>44</volume><fpage>S27</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">17278083</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Tleyjeh</surname><given-names>IM</given-names></name><name><surname>Tlaygeh</surname><given-names>HM</given-names></name><name><surname>Hejal</surname><given-names>R</given-names></name><etal/></person-group><article-title>The
impact of penicillin resistance on shot-term
mortality in hospitalized adults with pneumococcal
pneumonia: A systematic review and meta-analysis</article-title><source>Clin Infect Dis</source><year>2006</year><volume>42</volume><fpage>788</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">16477555</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Jan </surname><given-names>Verhoefa</given-names></name><name><surname>A </surname><given-names>Gillissen</given-names></name></person-group><article-title>
Resistant Haemophilus
influenzae in community-acquired respiratory tract
infections: a role for cefixime</article-title><source>J Antimicrob Agent</source><year>2003</year><volume>21</volume><fpage>6501</fpage><lpage>6509</lpage></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>KD</given-names></name></person-group><article-title>Penicillin-resistant pneumococci</article-title><source>J Hosp Infect</source><year>1991</year><volume>17</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">1672321</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Falco</surname><given-names>V</given-names></name><name><surname>Almirante</surname><given-names>B</given-names></name><name><surname>Jordano</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Influence
of penicillin resistance on outcome in adult patients
with invasive pneumococcal pneumonia: Is
penicillin useful against intermediately resistant
strains?</article-title><source> J Antimicrob Chemother</source><year>2004</year><volume>54</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">15215226</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Appelbaum</surname><given-names>PC</given-names></name></person-group><article-title>World-wide development of
antibiotic resistance in pneumococci</article-title><source>Eur J Clin Microbiol</source><year>1987</year><volume>6</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">3311732</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wierzbowski</surname><given-names>AK</given-names></name><name><surname>Nichol</surname><given-names>K</given-names></name><name><surname>Laing</surname><given-names>N</given-names></name><etal/></person-group><article-title>Macrolide resistance mechanisms among
Streptococcus pneumoniae isolated over 6 years of
Canadian Respiratory Organism Susceptibility
study (CROSS) (1998-2004)</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>60</volume><fpage>733</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">17673477</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Gleason</surname><given-names>PP</given-names></name><name><surname>Kapoor</surname><given-names>WN</given-names></name><name><surname>Stone</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Medical
outcomes and antimicrobial costs with the use of
the American Thoracic Society guidelines for
outpatients with community-acquired pneumonia</article-title><source>J Am Med Assoc</source><year>1997</year><volume>278</volume><fpage>32</fpage><lpage>39</lpage></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>VM</given-names></name><name><surname>Bauer</surname><given-names>AW</given-names></name></person-group><article-title>Antibiotic susceptibility
testing by a Standard Disc Method</article-title><source>AMJ Clin Path</source><year>1996</year><volume>36</volume><fpage>493</fpage><lpage>496</lpage></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="other" publisher-type="journal"><collab>Clinical and Laboratory Standards Institute</collab><article-title>Performance standard for antimicrobial disk susceptibility testing</article-title><source>Approved Standard</source><year>2006</year></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Pagarin</surname><given-names>F</given-names></name><name><surname>Lilienthal</surname><given-names>F</given-names></name><name><surname>Bourdin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Community- acquired pneumonia: Assessment of microbial aetiology as mortality factor</article-title><source>Eur Respir J</source><year>2004</year><volume>24</volume><fpage>779</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">15516672</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Oncu</surname><given-names>S</given-names></name><name><surname>Erdem</surname><given-names>H</given-names></name><name><surname>Pahsa</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic options for pneumococcal pneumonia in Turkey</article-title><source>Clin Ther</source><year>2005</year><volume>27</volume><fpage>674</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">16117975</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Okesola</surname><given-names>AO</given-names></name><name><surname>Ige</surname><given-names>OM</given-names></name></person-group><article-title>Trends in bacterial
pathogens of lower respiratory tract infections</article-title><source>The Ind J Chest Dis &#x00026; All Sci</source><year> 2007</year><volume>50</volume><fpage>269</fpage><lpage>273</lpage></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Okesola</surname><given-names>AO</given-names></name><name><surname>Ige</surname><given-names>OM</given-names></name></person-group><article-title>Occurrence of antibiotic
resistance and extended-spectrum B-lactamace
production among bacterial respiratory pathogens
in Nigeria</article-title><source>Int J Pharm Biomed Sci</source><year> 2012</year><volume>3</volume><issue>3</issue><fpage>85</fpage><lpage>88</lpage></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>Mandell</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Practice
guidelines for the management of communityacquired
pneumonia in adults. Infectious Diseases Society of America</article-title><source>Clin Infect Dis</source><year>2000</year><volume>31</volume><fpage>347</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">10987697</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Mandell</surname><given-names>LA</given-names></name><name><surname>Marrie</surname><given-names>TJ</given-names></name><name><surname>Grosman</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Canadian guidelines for the initial management of community-acquired pneumonia: an evidencebased update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group</article-title><source>Clin Infect Dis</source><year> 2000</year><volume>31</volume><fpage>383</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">10987698</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>File</surname><given-names>TM Jr</given-names></name><name><surname>Garau</surname><given-names>J</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Guidelines for
empiric antimicrobial prescribing in communityacquired
pneumonia</article-title><source>Chest</source><year>2004</year><volume>125</volume><fpage>1888</fpage><lpage>1901</lpage><pub-id pub-id-type="pmid">15136404</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Niederman</surname><given-names>MS</given-names></name><name><surname>Mandell</surname><given-names>LA</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Guidelines for the management of adults with
community-acquired pneumonia. Diagnosis,
assessment of severity, antimicrobial therapy, and
prevention</article-title><source>Am J Respir Crit Care Med</source><year> 2001</year><volume>163</volume><fpage>1730</fpage><lpage>1754</lpage><pub-id pub-id-type="pmid">11401897</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Jay</surname><given-names>SJ</given-names></name><name><surname>Johnson</surname><given-names>WG</given-names></name><name><surname>Pierce</surname><given-names>AK</given-names></name></person-group><article-title>The radiographic
resolution of Streptococcus pneumonia</article-title><source>N Engl
J Med</source><year> 1975</year><volume>293</volume><fpage>798</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">1160971</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Ort</surname><given-names>S</given-names></name><name><surname>Ryan</surname><given-names>JL</given-names></name><name><surname>Barden</surname><given-names>G</given-names></name><name><surname>D Esopo</surname><given-names>N</given-names></name></person-group><article-title>Pneumococcal
pneumonia: Clinical and radiological
presentations</article-title><source>JAMA</source><year>1983</year><volume>249</volume><fpage>214</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">6848806</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Markham</surname><given-names>A</given-names></name><name><surname>Brogden</surname><given-names>RN</given-names></name></person-group><article-title>Cefixime: a review
of its therapeutic efficacy in lower respiratory tract
infections</article-title><source>Drugs</source><year>1995</year><volume>49</volume><fpage>1007</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">7641600</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Kiani</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Nelson</surname><given-names>B</given-names></name></person-group><article-title>Comparative,
multicenter studies of cefixime and amoxicillin in
the treatment of respiratory tract infection</article-title><source>Am J
Med</source><year>1988</year><volume>85</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">3048092</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Modal</surname><given-names>J</given-names></name></person-group><article-title>Efficacy and tolerability of cefixime in
lower respiratory tract infections in adults: French
multicenter study</article-title><source>Press Med</source><year>1989</year><volume>18</volume><fpage>1605</fpage><lpage>1607</lpage></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Quintiliani</surname><given-names>R</given-names></name></person-group><article-title>Cefixime in the treatment of
patients with lower respiratory tract infections:
results of US clinical trials</article-title><source>Clin Ther</source><year>1996</year><volume>18</volume><fpage>373</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">8829015</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Verghese</surname><given-names>A</given-names></name><name><surname>Roberson</surname><given-names>D</given-names></name><name><surname>Kailbfleisch</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Randomized comparative study of cefixime
versus cephalexin in acute bacterial exacerbations
of chronic bronchitis</article-title><source>Antimicrob Agent Chemother</source><year>1990</year><volume>34</volume><fpage>1041</fpage><lpage>1044</lpage></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Hamilton-Miller</surname></name></person-group><article-title>Overview of cefixime use in community-acquired pneumonia</article-title><source>Clin. Micro Infect</source><year>2000</year><volume>6</volume><issue>Suppl 3</issue><fpage>81</fpage><lpage>97</lpage></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Dreshai</surname><given-names>SH</given-names></name><name><surname>Doda-Ejupi-Ti</surname></name><name><surname>Tolai</surname><given-names>I Q</given-names></name><etal/></person-group><article-title>Clinical role of cefixime in community-acquired infections</article-title><source>Prilozi</source><year>2011</year><volume>32</volume><issue>2</issue><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">22286619</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cazzzola</surname><given-names>M</given-names></name><name><surname>Vinciguerra</surname><given-names>A</given-names></name><name><surname>Beghi</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Comparative evaluation of the clinical and
microbiological efficacy of co-amoxiclav vs
cefixime or ciprofloxacin in bacteria exacerbation
of chronic bronchitis</article-title><source>J Chemother</source><year> 1995</year><volume>7</volume><fpage>432</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">8596127</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="other" publisher-type="journal"><person-group person-group-type="author"><name><surname>Cogo</surname><given-names>R</given-names></name><name><surname>Monzani</surname><given-names>GP</given-names></name><name><surname>Caiazzzo</surname><given-names>G</given-names></name></person-group><article-title>Safety and
efficacy of cefixime vs ceftriaxone in the treatment
of infectious exacerbations of chronic bronchitis</article-title><source>J Drug Dev</source><year>1993</year><issue>Suppl, 1</issue><fpage>55</fpage><lpage>56</lpage></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>File</surname><given-names>TM Jr</given-names></name><name><surname>Marrie</surname><given-names>TJ</given-names></name></person-group><article-title>Burden of communityacquired
pneumonia in North American adults</article-title><source>Postgrad Med</source><year>2010</year><volume>122</volume><issue>2</issue><fpage>130</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">20203464</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Marrie</surname><given-names>TJ</given-names></name><name><surname>Poulin-Costello</surname><given-names>M</given-names></name><name><surname>Beecroft</surname><given-names>MD</given-names></name><name><surname>Herman-Gnjidic</surname><given-names>Z</given-names></name></person-group><article-title>Etiology of communityacquired
pneumonia treated in an ambulatory
setting</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><issue>1</issue><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">15672850</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal" publisher-type="journal"><person-group person-group-type="author"><name><surname>Wootton</surname><given-names>D</given-names></name></person-group><article-title>The review of diagnosis, aetiology
and severity of community-acquired pneumonia
in adults</article-title><source>Afri J of Respir Med</source><year>2010</year><month>3</month><volume>4</volume><fpage>55</fpage><lpage>58</lpage></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1:</label><caption><p>Anthropometric characteristics of patients in the 2 arms of treatment.</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Anthropometric characteristics</th><th align="left" rowspan="1" colspan="1">Drug Group</th><th align="left" rowspan="1" colspan="1">Sample Size N</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">Standard Deviation</th><th align="left" rowspan="1" colspan="1">T-value</th><th align="left" rowspan="1" colspan="1">P-Value</th></tr><tr><th colspan="7" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age(yrs)</td><td rowspan="1" colspan="1">Cefixime</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">44.6</td><td rowspan="1" colspan="1">18.59</td><td rowspan="1" colspan="1">-0.50</td><td rowspan="1" colspan="1">0.62</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ciprofloxacin</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">46.7</td><td rowspan="1" colspan="1">17.10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">Cefixime</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">62.1</td><td rowspan="1" colspan="1">12.45</td><td rowspan="1" colspan="1">-1.67</td><td rowspan="1" colspan="1">0.10</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ciprofloxacin</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">14.61</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Height (cm)</td><td rowspan="1" colspan="1">Cefixime</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">162.6</td><td rowspan="1" colspan="1">8.15</td><td rowspan="1" colspan="1">0.65</td><td rowspan="1" colspan="1">0.52</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ciprofloxacin</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">161.5</td><td rowspan="1" colspan="1">5.97</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2:</label><caption><p>Summary Statistics of the duration of Symptoms in days of patients allocated to cefixime and ciprofloxacin treatment groups.</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">DRUG</th><th align="left" rowspan="1" colspan="1">FEVER</th><th align="left" rowspan="1" colspan="1">COUGH</th><th align="left" rowspan="1" colspan="1">COUGH WITH SPUTUM</th><th align="left" rowspan="1" colspan="1">CHILLS AND RIGORS</th><th align="left" rowspan="1" colspan="1">CATARRH</th><th align="left" rowspan="1" colspan="1">HEADACHE</th><th align="left" rowspan="1" colspan="1">CHEST PAIN</th></tr><tr><th colspan="8" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Cefixime</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">6.12</td><td rowspan="1" colspan="1">9.38</td><td rowspan="1" colspan="1">5.00</td><td rowspan="1" colspan="1">4.11</td><td rowspan="1" colspan="1">8.26</td><td rowspan="1" colspan="1">5.17</td><td rowspan="1" colspan="1">5.54</td></tr><tr><td rowspan="1" colspan="1">Median</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">10.00</td><td rowspan="1" colspan="1">7.0</td><td rowspan="1" colspan="1">3.00</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">7.00</td></tr><tr><td rowspan="1" colspan="1">N</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1"><bold>Ciprofloxacin</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">6.87</td><td rowspan="1" colspan="1">10.50</td><td rowspan="1" colspan="1">6.32</td><td rowspan="1" colspan="1">6.86</td><td rowspan="1" colspan="1">8.82</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1">6.65</td></tr><tr><td rowspan="1" colspan="1">Median</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">10.00</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">10.00</td><td rowspan="1" colspan="1">7.0</td><td rowspan="1" colspan="1">7.0</td></tr><tr><td rowspan="1" colspan="1">N</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1"><bold>TOTAL</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Mean</td><td rowspan="1" colspan="1">6.48</td><td rowspan="1" colspan="1">9.89</td><td rowspan="1" colspan="1">5.68</td><td rowspan="1" colspan="1">5.31</td><td rowspan="1" colspan="1">8.53</td><td rowspan="1" colspan="1">5.4</td><td rowspan="1" colspan="1">6.1</td></tr><tr><td rowspan="1" colspan="1">Median</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">10.00</td><td rowspan="1" colspan="1">7.00</td><td rowspan="1" colspan="1">6.00</td><td rowspan="1" colspan="1">8.00</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">N</td><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">52</td></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3:</label><caption><p>Summary of statistics of patients' clinical characteristics on each day of follow-up in each treatment group.</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Day of Exam.</th><th align="left" rowspan="1" colspan="1">Clinical Assessment</th><th align="left" rowspan="1" colspan="1">Cefixime Mean (SD) n = 39</th><th align="left" rowspan="1" colspan="1">Ciprofloxacin Mean (SD) n = 34</th><th align="left" rowspan="1" colspan="1">t-value</th><th align="left" rowspan="1" colspan="1">p-value</th></tr><tr><th colspan="6" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">TEMP</td><td rowspan="1" colspan="1">37.9(0.7)</td><td rowspan="1" colspan="1">37.8(0.5)</td><td rowspan="1" colspan="1">0.77</td><td rowspan="1" colspan="1">0.44</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PR</td><td rowspan="1" colspan="1">110.5(162.0)</td><td rowspan="1" colspan="1">93.0 (8.0)</td><td rowspan="1" colspan="1">0.77</td><td rowspan="1" colspan="1">0.34</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">RR</td><td rowspan="1" colspan="1">21.4(2.5)</td><td rowspan="1" colspan="1">22.1(3.2)</td><td rowspan="1" colspan="1">-1.06</td><td rowspan="1" colspan="1">0.29</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">TEMP</td><td rowspan="1" colspan="1">37.2(0.9)</td><td rowspan="1" colspan="1">37.5(0.5)</td><td rowspan="1" colspan="1">-1.21</td><td rowspan="1" colspan="1">0.23</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PR</td><td rowspan="1" colspan="1">103.9(147.6)</td><td rowspan="1" colspan="1">81.1(18.6)</td><td rowspan="1" colspan="1">0.89</td><td rowspan="1" colspan="1">0.38</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">RR</td><td rowspan="1" colspan="1">21.5(11.2)</td><td rowspan="1" colspan="1">20.7(2.6)</td><td rowspan="1" colspan="1">0.38</td><td rowspan="1" colspan="1">0.69</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">TEMP</td><td rowspan="1" colspan="1">36.8(0.8)</td><td rowspan="1" colspan="1">37.2(0.5)</td><td rowspan="1" colspan="1">-2.64</td><td rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T3F1">*</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PR</td><td rowspan="1" colspan="1">76.0(6.4)</td><td rowspan="1" colspan="1">79.8(18.8)</td><td rowspan="1" colspan="1">-2.14</td><td rowspan="1" colspan="1">0.04<xref ref-type="table-fn" rid="T3F1">*</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">RR</td><td rowspan="1" colspan="1">17.3(1.4)</td><td rowspan="1" colspan="1">18.7(2.7)</td><td rowspan="1" colspan="1">-2.68</td><td rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T3F1">*</xref></td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">TEMP</td><td rowspan="1" colspan="1">36.8(0.4)</td><td rowspan="1" colspan="1">37.0(0.5)</td><td rowspan="1" colspan="1">-2.36</td><td rowspan="1" colspan="1">0.02<xref ref-type="table-fn" rid="T3F1">*</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PR</td><td rowspan="1" colspan="1">75.1(6.6)</td><td rowspan="1" colspan="1">77.7(8.0)</td><td rowspan="1" colspan="1">-1.42</td><td rowspan="1" colspan="1">0.16</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">RR</td><td rowspan="1" colspan="1">16.5(1.1)</td><td rowspan="1" colspan="1">17.7(2.5)</td><td rowspan="1" colspan="1">-2.58</td><td rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T3F1">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T3F1"><label>*</label><p>Statistically significant differences between the two treatment groups.</p></fn><fn id="T3F2"><p><italic>TEMP</italic>= <italic>Temperature</italic></p><p><italic>PR</italic>= <italic>Pulse rate</italic></p><p><italic>RR</italic>= <italic>Respiratory rate</italic></p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4:</label><caption><p>Percentage bacteria eradication rate and radiological clearance at follow-up of patients in Cefixime and Ciprofloxacin groups.</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Type of follow up</th><th align="left" rowspan="1" colspan="1">Days</th><th align="left" rowspan="1" colspan="1">Cefixime No (%)</th><th align="left" rowspan="1" colspan="1">Ciprofloxacin No (%)</th><th align="left" rowspan="1" colspan="1">&#x003c7;2-value</th><th align="left" rowspan="1" colspan="1">P - value</th></tr><tr><th colspan="6" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1.Radiological clearance</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">39(100.0)</td><td rowspan="1" colspan="1">34(100.0)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">4(10.3)</td><td rowspan="1" colspan="1">13(38.2)</td><td rowspan="1" colspan="1">7.96</td><td rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="T4F1">*</xref></td></tr><tr><td rowspan="1" colspan="1">2. Microbiological (Bacterial eradication rate)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">39(100.0)</td><td rowspan="1" colspan="1">34(100.0)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">30(76.9)</td><td rowspan="1" colspan="1">29(85.3)</td><td rowspan="1" colspan="1">0.82</td><td rowspan="1" colspan="1">0.37</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">5(12.8)</td><td rowspan="1" colspan="1">21(61.8)</td><td rowspan="1" colspan="1">18.98</td><td rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="T4F1">*</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">3(7.7)</td><td rowspan="1" colspan="1">13(38.2)</td><td rowspan="1" colspan="1">9.90</td><td rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="T4F1">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T4F1"><label>*</label><p>Statistically significant differences between the 2 treatment groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5:</label><caption><p>Distribution of the lung lesions and percentage clearance on days 1 and 14 in Cefixime and Ciprofloxacin drug groups.</p></caption><table frame="hsides" rules="none" width="100%"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Cefixime No (%)</th><th align="left" rowspan="1" colspan="1">Ciprofloxacin No (%)</th><th align="left" rowspan="1" colspan="1">TOTAL No (%)</th></tr><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Left Lower Zone</td><td rowspan="1" colspan="1">Day 1</td><td rowspan="1" colspan="1">25 (64.1)</td><td rowspan="1" colspan="1">25(73.5)</td><td rowspan="1" colspan="1">50(68.5)</td></tr><tr><td rowspan="1" colspan="1">Left Lower Zone</td><td rowspan="1" colspan="1">Day 14</td><td rowspan="1" colspan="1">2(5.1)</td><td rowspan="1" colspan="1">10(29.4)</td><td rowspan="1" colspan="1">12(16.4)</td></tr><tr><td rowspan="1" colspan="1">Left Mid &#x00026; Lower Zone</td><td rowspan="1" colspan="1">Day 1</td><td rowspan="1" colspan="1">3(7.7)</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1">3(4.1)</td></tr><tr><td rowspan="1" colspan="1">Right Lower Zone</td><td rowspan="1" colspan="1">Day 14</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Left Mid Zone</td><td rowspan="1" colspan="1">Day 1</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1">1(2.9)</td><td rowspan="1" colspan="1">1(1.4)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Day 14</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Right Lower Zone</td><td rowspan="1" colspan="1">Day 1</td><td rowspan="1" colspan="1">10( 25.6)</td><td rowspan="1" colspan="1">7(20.6)</td><td rowspan="1" colspan="1">17(23.3)</td></tr><tr><td rowspan="1" colspan="1">Right Lower Zone</td><td rowspan="1" colspan="1">Day 14</td><td rowspan="1" colspan="1">2(5.1)</td><td rowspan="1" colspan="1">3(8.8)</td><td rowspan="1" colspan="1">5(6.8)</td></tr><tr><td rowspan="1" colspan="1">Right Mid Zone</td><td rowspan="1" colspan="1">Day 1</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1">1(2.9)</td><td rowspan="1" colspan="1">1(1.4)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Day 14</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Right Upper Zone</td><td rowspan="1" colspan="1">Day 1</td><td rowspan="1" colspan="1">1(2.6)</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1">1(1.4)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Day 14</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="T5F1"><p>Left lower and right lower zones were the zones mostly affected by the consolidative changes on chest-x-ray accounting for 92.1%.</p></fn></table-wrap-foot></table-wrap></floats-group></article>